Saturday, December 06, 2025 | 11:42 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Laurus Labs hits record high on robust September quarter results

The company's Ebitda margins improved 1,349 basis points to 32.8 per cent due to better product mix and improved operating leverage

pharmacy, drugs, medicine, pharma companies, pharmaceuticals, vaccine, coronavirus, covid, testing
premium

According to virologists, there are four phases to developing a vaccine.

SI Reporter Mumbai
Laurus Labs hit record high of Rs 345 after rising 4.5 per cent on the BSE on Friday after the company reported a robust set of July-September quarter (Q2FY21) numbers. The pharmaceutical company's stock surpassed its previous high of Rs 343.20, touched on October 8, 2020.

At 09:26 am, Laurus Labs had erased its morning gain and was trading 1 per cent higher at Rs 332 on the BSE, as compared to 0.26 per cent rise in the S&P BSE Sensex. A combined 3.5 million equity shares had changed hands in the first 10 minutes of trade on the